and Experience: 10+ years related commercial experience At least 5 years of marketing experience in pharma industry and people... management experience In depth knowledge of Japan healthcare environment and systems Pharma sales experience is an advantage...
求人の要約 給与 年収 1,600 〜 2,000万円 職種 マーケティング、調査、マーケティングコミュニケーション、広報(PR) 勤務地 東京23区 求人詳細 As a Government Affairs Lead, you will lead public activities, mainly on policy development. You will also contribute to the company's policy-focused activ...
Crude prices came under pressure after US data pointed to persistent labour market strength which further dimmed prospects of an early decline in US interest rates. Continue Reading »
Freshworks now expects annual revenue between $695 million and $705 million, compared with its previous forecast of $703.5 million to $711.5 million. Continue Reading »
While gold is traditionally considered a hedge against inflation, high interest rates kept by the US Fed to tame the rising prices can increase the opportunity cost of holding the non-yielding bullion. Continue Reading »
Manpansand Beverages' top officials have been asked to pay penalties totaling ₹74 lakh by SEBI for violations including misstating and manipulating financial statements. Continue Reading »
Stock Market Today- Cipla, Aurobindo, Torrent are 3 preferred picks of HSBC Research on healthy Q4 expectations. HSBC expects 38.4% y-o-y rise in net profit of pharma companies in their coverage during Q4 helped by rising US sales compensating for slower growth in India Continue Reading »
SK Finance's proposed IPO is a combination of a fresh issue of equity shares worth ₹500 crore and an OFS of up to ₹1,700 crore by promoters and investor shareholders Continue Reading »
Emudhra, a leading certifying authority in India, has seen its stock value surge by 245% in the past year, reaching ₹738.40. Centrum Broking in its recent note revised its price target price on the stock to ₹832 apiece. Reflecting on a strong spike in the share price, it adjusted its rating. Continue Reading »
Post FY24 results, most brokerage houses have kept their target price for Tata Chemicals at least 10% lower than the current market price Continue Reading »